Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

S. Gabriel, E. Creagan, W. M. O'Fallon, J. Jaquith, T. W. Bunch

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

Original languageEnglish (US)
Pages (from-to)460-465
Number of pages6
JournalJournal of Rheumatology
Volume17
Issue number4
StatePublished - 1990

Fingerprint

Methotrexate
Rheumatoid Arthritis
Blood Sedimentation
Hand Strength
Therapeutics
Arthritis
Joints
Physicians

Keywords

  • methotrexate
  • rheumatoid arthritis
  • treatment

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Gabriel, S., Creagan, E., O'Fallon, W. M., Jaquith, J., & Bunch, T. W. (1990). Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. Journal of Rheumatology, 17(4), 460-465.

Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. / Gabriel, S.; Creagan, E.; O'Fallon, W. M.; Jaquith, J.; Bunch, T. W.

In: Journal of Rheumatology, Vol. 17, No. 4, 1990, p. 460-465.

Research output: Contribution to journalArticle

Gabriel, S, Creagan, E, O'Fallon, WM, Jaquith, J & Bunch, TW 1990, 'Treatment of rheumatoid arthritis with higher dose intravenous methotrexate', Journal of Rheumatology, vol. 17, no. 4, pp. 460-465.
Gabriel S, Creagan E, O'Fallon WM, Jaquith J, Bunch TW. Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. Journal of Rheumatology. 1990;17(4):460-465.
Gabriel, S. ; Creagan, E. ; O'Fallon, W. M. ; Jaquith, J. ; Bunch, T. W. / Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. In: Journal of Rheumatology. 1990 ; Vol. 17, No. 4. pp. 460-465.
@article{12ba880f012e420d819888b5700801a1,
title = "Treatment of rheumatoid arthritis with higher dose intravenous methotrexate",
abstract = "A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.",
keywords = "methotrexate, rheumatoid arthritis, treatment",
author = "S. Gabriel and E. Creagan and O'Fallon, {W. M.} and J. Jaquith and Bunch, {T. W.}",
year = "1990",
language = "English (US)",
volume = "17",
pages = "460--465",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

AU - Gabriel, S.

AU - Creagan, E.

AU - O'Fallon, W. M.

AU - Jaquith, J.

AU - Bunch, T. W.

PY - 1990

Y1 - 1990

N2 - A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

AB - A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

KW - methotrexate

KW - rheumatoid arthritis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0025329610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025329610&partnerID=8YFLogxK

M3 - Article

C2 - 2348423

AN - SCOPUS:0025329610

VL - 17

SP - 460

EP - 465

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -